Keyron is a technology company.
Keyron has raised $3.0M across 2 funding rounds.
Keyron has raised $3.0M in total across 2 funding rounds.
Keyron Limited is a London-based medical technology company founded in 2016 that develops innovative, non-invasive medical devices for treating metabolic diseases, including obesity (Class II & III, BMI ≥35), type 2 diabetes, NASH (non-alcoholic steatohepatitis), and liver fibrosis.[1][2][4] Its flagship product, ForePass, is the world's first fully reversible, perforation-free gastric bypass device—a Class III implantable medical device delivered endoscopically without incisions or sutures, combining a gastric balloon and intestinal sleeve to mimic metabolic surgery's effects, enabling substantial weight loss (targeting 30%+), diabetes reversal, and NASH improvement for ~55 million patients in the US and EU5 who reject surgery (99% refusal rate) or fail/quit drugs (92% fail 15% loss; 85% quit).[2][3][4] Keyron serves patients with severe "diabesity" (obesity + diabetes/comorbidities), addressing a gap where surgery is invasive and drugs underperform, with preclinical trials showing safety in swine and efficacy (diabetes/NASH reversal) in rodents; the company has raised funding from investors like Health Wildcatters (2024 cohort) and operates with <25 employees and revenue under $5M.[1][2][3]
Keyron was founded in 2016 in London, UK (headquartered at 57a Epirus Road, Fulham), by a team of globally renowned experts in diabesity, endoscopy, metabolic surgery, medical device engineering, and business leaders with track records in obesity/medtech exits.[1][2][4] Key team members include Giorgio Castagneto-Gissey, a Research Associate in Energy Economics at University College London (UCL) and employee at Keyron.[1] The idea for ForePass emerged from identifying the unmet need in severe diabesity treatment—where 99% refuse surgery despite needing 30%+ weight loss, and drugs fail most—leading to the invention of a non-surgical alternative that replicates gastric bypass via endoscopic delivery.[3][4] Early traction includes patented technology proven safe/effective in preclinical animal trials (diabetes/NASH reversal in rodents, safety in swine), participation in Health Wildcatters 2024 accelerator, and additional undisclosed investors, positioning it as a platform for replicating multiple bariatric surgeries.[1][3][4]
Keyron stands out in medtech through ForePass's engineering and clinical advantages:
Keyron rides the explosive metabolic disease medtech wave, fueled by surging obesity/diabetes epidemics (55M US/EU5 severe cases; 360-400M worldwide potential), limitations of GLP-1 drugs (high dropout, modest loss), and demand for surgery alternatives amid ~99% refusal rates.[2][3][4] Timing is ideal post-2020s GLP-1 boom (e.g., Ozempic/Wegovy), as drugs leave ~46M patients underserved, creating space for durable, reversible devices like ForePass that match surgery outcomes without invasiveness.[4] Market forces favoring Keyron include aging populations, rising NASH/liver fibrosis, regulatory push for cost-effective Class III devices, and investor interest in healthtech (e.g., Health Wildcatters backing).[1][2] It influences the ecosystem by pioneering "next-gen metabolic platforms," potentially resetting standards for endoscopy-based treatments and bridging pharma/surgery gaps.
Keyron is poised to disrupt diabesity care with ForePass advancing to human trials, leveraging preclinical wins and expert backing to capture a massive underserved market beyond drugs/surgery.[3][4] Next steps likely include clinical validation, FDA/EU approvals, partnerships with endosurgeons/hospitals, and scaling as a bariatric platform—watch for 2026+ trial data amid GLP-1 fatigue.[2][4] Trends like AI-optimized devices, personalized metabolic therapies, and global obesity surges will amplify its trajectory, evolving Keyron from innovator to category leader in non-invasive medtech, unlocking life-changing solutions for millions where current options fall short.[1][3]
Keyron has raised $3.0M in total across 2 funding rounds.
Keyron's investors include Health Wildcatters, LIFTT.
Keyron has raised $3.0M across 2 funding rounds. Most recently, it raised $30K Seed in September 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2024 | $30K Seed | Health Wildcatters | |
| Dec 1, 2021 | $3.0M Seed | LIFTT |